Venus Concept Inc. (VERO)
NASDAQ: VERO · Real-Time Price · USD
2.690
+0.320 (13.50%)
At close: Oct 8, 2025, 4:00 PM EDT
2.490
-0.200 (-7.43%)
After-hours: Oct 8, 2025, 7:15 PM EDT
Venus Concept Revenue
Venus Concept had revenue of $15.69M in the quarter ending June 30, 2025, a decrease of -5.37%. This brings the company's revenue in the last twelve months to $60.11M, down -13.90% year-over-year. In the year 2024, Venus Concept had annual revenue of $64.83M, down -15.09%.
Revenue (ttm)
$60.11M
Revenue Growth
-13.90%
P/S Ratio
0.04
Revenue / Employee
$205,846
Employees
292
Market Cap
5.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.83M | -11.52M | -15.09% |
| Dec 31, 2023 | 76.35M | -23.14M | -23.26% |
| Dec 31, 2022 | 99.50M | -6.13M | -5.80% |
| Dec 31, 2021 | 105.62M | 27.61M | 35.39% |
| Dec 31, 2020 | 78.01M | -32.39M | -29.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VERO News
- 6 days ago - Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction - GlobeNewsWire
- 7 days ago - Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025 - GlobeNewsWire
- 19 days ago - Cellulite Treatment Market Size to Reach USD 5.19 Billion by 2032, Driven by Rising Demand for Non-Invasive Aesthetic Solutions | S&S Insider - GlobeNewsWire
- 7 weeks ago - Venus Concept Inc. (VERO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Venus Concept Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025 - GlobeNewsWire
- 3 months ago - Venus Concept Announces $6.5 Million Debt-to-Equity Exchange Transaction - GlobeNewsWire
- 4 months ago - Venus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire